pharma · Clear Cell Renal Cell Carcinoma · Cushing s Syndrome
Peking University Biologics
Peking University Third Hospital
Peking University Biologics clinical programs — 6 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 仙霞路, 319号, 上海市, 长宁区, CN
- Founded
- 2018
- Employees
- 8
- Programs
- 15
- Drugs
- 25
- Patents
- 0
Peking University Biologics projects
6 ClinicalTrials.gov programs sponsored by Peking University Biologics.
Peking University Biologics has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
68Ga-NY104 PET/CT
Peking University Third Hospital
Clear Cell Renal Cell Carcinoma
1 trial -
68Ga-Pentixafor
Peking University Third Hospital
Cushing s Syndrome
1 trial -
Glofitamab
Peking University Third Hospital
MCL
1 trial -
Luveris
Peking University Third Hospital
Infertility
1 trial -
Roxadustat
Peking University Third Hospital
Coronary Artery Bypass
1 trial -
recombinant human endostatin
Peking University Third Hospital
Melanoma
1 trial
Frequently asked questions
How many clinical projects does Peking University Biologics have?
6 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.